Condition: Nonalcoholic Steatohepatitis · Sponsor: Second Genome
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in subjects with fibrosis stage 1-3 (F1-F3) NASH.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Second Genome Clinical Site 405 | Chandler, Arizona, United States | — |
| Second Genome Clinical Site 406 | Tucson, Arizona, United States | — |
| Second Genome Clinical Site 403 | Panorama City, California, United States | — |
| Second Genome Clinical Site 409 | Lakewood Rch, Florida, United States | — |
| Second Genome Clinical Site 410 | Flowood, Mississippi, United States | — |
| Second Genome Clinical Site 404 | Kansas City, Missouri, United States | — |
| Second Genome Clinical Site 408 | Fayetteville, North Carolina, United States | — |
| Second Genome Clinical Site 407 | Clarksville, Tennessee, United States | — |
| Second Genome Clinical Site 402 | Austin, Texas, United States | — |
| Second Genome Clinical Site 401 | San Antonio, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03676231